Expert Q&A
Should we launch ourselves in Europe or consider partnering/outlicensing, and how do we decide?
Explore how biopharma leaders weigh launching independently versus partnering in Europe, and how to decide.
Read moreResources
Discover a collection of resources tailored for biopharma companies looking to enter the European market.
Expert Q&A
Launching in EU – Q&A 8
What risk areas should we pay special attention to (pharmacovigilance, legal, compliance, etc.) when launching in Europe?
Read more
Expert Q&A
What are the key operational flows we need to set up for product distribution in Europe?
What are the key operational flows we need to set up for product distribution in Europe? What's Inside the Q&A: Quality Oversight Frameworks Discover how Europe’s unique release and certification…
Read more
Expert Q&A
What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?
What are Early Access Programs (EAPs) in Europe, and how can they help gather real-world data?
Read moreExpert Q&A
First interactions with EMA – Q&A 6
What CMC (Chemistry, Manufacturing, and Controls) expectations in the EU might surprise biopharma companies?
Read more
Expert Q&A
First interactions with EMA – Q&A 5
Get expert insights on your first interactions with the European Medicines Agency. Learn how to choose the right regulatory pathway, compare timelines, and navigate EU procedures with confidence.
Read more
Expert Q&A
What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?
What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?
Read more
Expert Q&As
First interactions with EMA – Q&A 3
Why is early engagement with EMA, payers, KOLs, and patient groups so important?
Read more
Expert Q&A
How do we ensure compliance with local promotional regulations and get our marketing materials approved in Europe?
How do we ensure compliance with local promotional regulations and get our marketing materials approved in Europe?
Read more
Expert Q&A
How should we plan our launch sequencing across European countries, considering timelines for approval, pricing, and access?
How should we plan our launch sequencing across European countries, considering timelines for approval, pricing, and access?
Read more